Vera Therapeutics
VERA
178 hedge funds and large institutions have $2.66B invested in Vera Therapeutics in 2024 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 97 increasing their positions, 36 reducing their positions, and 23 closing their positions.
169% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 36
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
39% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 23
12% more capital invested
Capital invested by funds: $2.37B → $2.66B (+$295M)
3% more funds holding
Funds holding: 173 → 178 (+5)
1.75% more ownership
Funds ownership: 97.61% → 99.36% (+1.7%)
49% less call options, than puts
Call options by funds: $2.4M | Put options by funds: $4.68M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$57.6M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$47.6M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$32.2M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$29.7M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$28.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$39.6M |
| 2 |
CC
Commodore Capital
New York
|
-$22.9M |
| 3 |
EP
Eversept Partners
New York
|
-$19.9M |
| 4 |
ACM
Altium Capital Management
New York
|
-$11.2M |
| 5 |
Millennium Management
New York
|
-$9.69M |
VERA Hedge Fund Activity: Q4 2024 in Review
178 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Vera Therapeutics (VERA) for Q4 2024, worth a combined $2.66B — up 12% from $2.37B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new VERA positions and 23 closed out — a net gain of 9 holders — while 97 added to existing stakes and 36 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $57.6M. The largest seller was Adage Capital Partners, cutting an estimated $39.6M.
- 178 institutional investors held Vera Therapeutics (VERA) as of Q4 2024, up from 173 in Q3 2024.
- Funds reported $2.66B of Vera Therapeutics stock for Q4 2024, up 12% quarter-over-quarter.
- 32 funds opened new Vera Therapeutics positions in Q4 2024 and 23 closed out, a net change of +9 holders.
- The largest Vera Therapeutics buyer in Q4 2024 was Avoro Capital Advisors, an estimated $57.6M added.
- The largest Vera Therapeutics seller in Q4 2024 was Adage Capital Partners, an estimated $39.6M sold.
Based on aggregated 13F filings for Q4 2024.